ArticleVaccine2022
Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum.
Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Neurosyphilis-Induced Psychosis in Europe: A Systematic Review of Case Reports.Pathogens (Basel, Switzerland) · 2024Pooled it
- Looking Down the Road: Development of a Future Syphilis Vaccine.Sexually transmitted diseases · 2026Article
- The Global Syphilis Epidemic: Turning the Tide.Sexually transmitted diseases · 2026Article
- Innovations and Challenges in Syphilis Screening and Prevention Among Men Who Have Sex With Men: A Scoping Review.Sexually transmitted diseases · 2026Article
- A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development.NPJ vaccines · 2026Article
- Article
- Vaxjo 2.0: An ontology- and large language model-powered knowledge base of vaccine adjuvants and mechanisms.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Protective immunity induced by Tp0136 epitope vaccines with mRNA LNP or protein delivery.NPJ vaccines · 2025Article
- Review
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- Syphilis and the Eye: Clinical Features, Diagnostic Challenges, and Evolving Therapeutic Paradigms.Pathogens (Basel, Switzerland) · 2025Review
- Article
- B-Cell Epitope Mapping of theDiagnostics (Basel, Switzerland) · 2025Article
- Identification of antibodies induced by immunization with the syphilis vaccine candidate Tp0751.Vaccine · 2025Article
- Time-course transcriptomics reveals the impact ofFrontiers in microbiology · 2025Article
- A comprehensive strategy for the development of a multi-epitope vaccine targetingFrontiers in microbiology · 2025Article
- Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.Human vaccines & immunotherapeutics · 2024Article
- Treponema pallidum Periplasmic and Membrane Proteins Are Recognized by Circulating and Skin CD4+ T Cells.The Journal of infectious diseases · 2024Article
- Evaluation of a minimal array ofMicrobiology spectrum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Syphilis continues to be a significant public health concern worldwide. The disease is endemic in many low- and middle-income countries, and rates have risen sharply in high-income countries over the last decade. The continued prevalence of infectious and congenital syphilis worldwide highlights the need for the development of an effective syphilis vaccine to complement public health measures for syphilis control. The complex, multi-stage course of syphilis infection necessitates a holistic approach to the development of an effective vaccine, in which immunization prevents both the localized stage of infection (typified by the highly infectious chancre) and the disseminated stages of infection (typified by the secondary rash, neurosyphilis, and destructive tertiary lesions, as well as congenital syphilis). Inhibiting development of the infectious chancre would reduce transmission thus providing community- level protection, while preventing dissemination would provide individual-level protection by reducing serious sequelae and may also provide community level protection by reducing shedding during secondary syphilis. In the current study we build upon prior investigations which demonstrated that immunizations with individual, well characterized T. pallidum TprK, TprC, and Tp0751 peptides elicits partial protection against infection in the animal model. Specifically, we show here that immunization with a TprC/TprK/Tp0751 tri-antigen cocktail protects animals from progressive syphilis lesions and substantially inhibits dissemination of the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.